Table 3 Characteristics of patients with severe exacerbations in the 12 months prior to MITT initiation and 12 months following MITT initiation.
12 months prior to MITT (pre index) (N = 667) | 12 months following MITT (post index) (N = 667) | |
|---|---|---|
Demographics | ||
Female, n (%) | 491 (73.6) | |
Age at asthma diagnosis, mean (SD) | 45.4 (15.8) | |
Age at MITT initiation, mean (SD) | 55.0 (13.8) | |
Years from diagnosis to MITT, mean (SD) | 9.6 (8.5) | |
Urban location, n (%) | 573 (85.9) | |
Smoking status, n (%) | ||
Non-smokera | 412 (61.8) | 414 (62.1) |
Smoker | 109 (16.3) | 102 (15.3) |
Former smoker | 131 (19.6) | 146 (21.9) |
Unknown | 15 (2.2) | 5 (0.7) |
BMIb | n = 376 | n = 302 |
BMI, mean (SD) kg/m2 | 30.4 (6.4) | 30.8 (6.4) |
Spirometryc, mean (SD) | n = 215 | n = 135 |
FEV1 % predicted value | 70.6 (19.1) | 74.7 (20.1) |
FEV1/FVC ratio | 69.6 (13.6) | 73.8 (13.5) |
Common comorbidities, n (%) | ||
Anxiety/depression | 272 (40.8) | |
Pneumonia | 32 (4.8) | |
Other respiratory infections | 233 (34.9) | |
Rhinitis | 131 (19.6) | |
Hypertension | 243 (36.4) | |
Diabetes mellitus | 79 (11.8) | |
Gastroesophageal reflux | 72 (10.8) | |
Conjunctivitis | 77 (11.5) | |
Polyposis | 51 (7.6) | |
Severe exacerbationsd, n (%) | 667 (100.0) | 352 (52.8) |
Blood eosinophils (%), mean (SD) | n = 425 4.1 (3.6) | n = 417 4.1 (3.3) |
